血清6-溴色氨酸水平被确定为CKD进展的危险因素
该研究在非裔美国人AASK队列(n=588)中分析APOL1风险等位基因与760种血清代谢物的关联,并在BioMe(n=678)和MDRD研究中验证。发现6-溴色氨酸水平越低,APOL1风险等位基因越多,且与CKD进展风险独立相关。
要点
- 低血清6-溴色氨酸水平与APOL1风险等位基因数量增多相关。
- 6-溴色氨酸水平较低与CKD进展风险升高独立相关。
- 6-溴色氨酸可能是跨种族的CKD进展新型风险标志物。
核心结论
- 血清6-溴色氨酸是CKD进展的一致且新型的危险因素。
研究设计与样本
- 在AASK队列588名参与者中评估APOL1风险等位基因与760种血清代谢物的关联,并在BioMe生物样本库678名黑人CKD参与者中重复验证。
- 在AASK、BioMe和MDRD研究中检验代谢物与CKD进展的关联。
主要发现
- 在AASK中,6-溴色氨酸与APOL1风险等位基因显著相关(P=4.7×10-5),并在BioMe中重复验证(P=5.7×10-3),水平越低风险等位基因越多。
- 在AASK、BioMe和MDRD研究中,较低的6-溴色氨酸水平与CKD进展相关,独立于人口学和临床特征(包括基线GFR)。
- 每两倍6-溴色氨酸水平升高的校正风险比:AASK为0.76(95%CI 0.64-0.91),BioMe为0.61(95%CI 0.43-0.85),MDRD为0.52(95%CI 0.34-0.79)。
- APOL1风险等位基因与6-溴色氨酸的交互作用不显著。
临床怎么用
- 血清6-溴色氨酸可能作为CKD进展的风险分层生物标志物,但需进一步验证和标准化检测方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Metabolite levels reflect physiologic homeostasis and may serve as biomarkers of disease progression. Identifying metabolites associated with APOL1 risk alleles-genetic variants associated with CKD risk commonly present in persons of African descent-may reveal novel markers of CKD progression relevant to other populations.Methods We evaluated associations between the number of APOL1 risk alleles and 760 serum metabolites identified via untargeted profiling in participants of the African American Study of Kidney Disease and Hypertension (AASK) (n=588; Bonferroni significance threshold P<6.5×10-5) and replicated findings in 678 black participants with CKD in BioMe, an electronic medical record-linked biobank. We tested the metabolite association with CKD progression in AASK, BioMe, and the Modification of Diet in Renal Disease (MDRD) Study.Results One metabolite, 6-bromotryptophan, was significant in AASK (P=4.7×10-5) and replicated in BioMe (P=5.7×10-3) participants, with lower levels associated with more APOL1 risk alleles. Lower levels of 6-bromotryptophan were associated with CKD progression in AASK and BioMe participants and in white participants in the MDRD Study, independent of demographics and clinical characteristics, including baseline GFR (adjusted hazard ratio per two-fold higher 6-bromotryptophan level, AASK, 0.76; 95% confidence interval [95% CI], 0.64 to 0.91; BioMe, 0.61; 95% CI, 0.43 to 0.85; MDRD, 0.52; 95% CI, 0.34 to 0.79). The interaction between the APOL1 risk alleles and 6-bromotryptophan was not significant. The identity of 6-bromotryptophan was confirmed in experiments comparing its molecular signature with that of authentic standards of other bromotryptophan isomers.Conclusions Serum 6-bromotryptophan is a consistent and novel risk factor for CKD progression.
引用
- Tin A, Nadkarni G, Evans AM, et al. Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression. J Am Soc Nephrol. 2018. PMID: 29777021. doi:10.1681/ASN.2017101064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。